The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months.

Sosenko JM, Skyler JS, Beam CA, Boulware D, Mahon JL, Krischer JP, Greenbaum CJ, Rafkin LE, Matheson D, Herold KC, Palmer JP, Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups
Diabetes Care. 2015 38 (5): 940-2

PMID: 25758770 · PMCID: PMC4407750 · DOI:10.2337/dc14-2787

OBJECTIVE - We developed a scale to serve as a potential end point for 6-month glycemic progression (PS6M) toward type 1 diabetes (T1D) in autoantibody-positive relatives of individuals with T1D.

RESEARCH DESIGN AND METHODS - The PS6M was developed from Diabetes Prevention Trial-Type 1 (DPT-1) data and tested in the TrialNet Pathway to Prevention Study (PTP). It is the difference between 6-month glucose sum values (30-120 min oral glucose tolerance test values) and values predicted for nonprogressors.

RESULTS - The PS6M predicted T1D in the PTP (P < 0.001). The area under the receiver operating chacteristic curve was greater (P < 0.001) for the PS6M than for the baseline-to-6-month difference. PS6M values were higher in those with two or more autoantibodies, 30-0 min C-peptide values <2.00 ng/mL, or DPT-1 Risk Scores >7.00 (P < 0.001 for all).

CONCLUSIONS - The PS6M is an indicator of short-term glycemic progression to T1D that could be a useful tool for assessing preventive treatments and biomarkers.

© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

MeSH Terms (15)

Adolescent Autoantibodies Biomarkers Blood Glucose C-Peptide Diabetes Mellitus, Type 1 Disease Progression Female Glucose Tolerance Test Humans Hyperglycemia Male Patient Acuity Risk Factors Severity of Illness Index

Connections (2)

This publication is referenced by other Labnodes entities:

Links